Analyst Price Targets — NVCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:55 am | — | UBS | $33.00 | $19.57 | TheFly | Nuvectis Pharma price target raised to $33 from $20 at Roth Capital |
| June 22, 2026 3:00 pm | — | H.C. Wainwright | $39.00 | $14.96 | TheFly | Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright |
| June 12, 2026 4:06 pm | — | H.C. Wainwright | $13.00 | $10.67 | TheFly | Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright |
| August 4, 2025 1:55 pm | — | H.C. Wainwright | $10.00 | $7.29 | TheFly | Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright |
Latest News for NVCT
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights: Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria…
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with…
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCT.
U.S. House Trading
No House trades found for NVCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.